this piece corresponds to the legacy myPDB login in the form of a bootstrap modal, will likely retire-->

Chemical Component Summary

Name(9cis)-retinoic acid
Identifiers(2E,4E,6Z,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoic acid
FormulaC20 H28 O2
Molecular Weight300.44 g/mol
Isomeric SMILESC\C(\C=C\C1=C(C)CCCC1(C)C)=C\C=C\C(\C)=C\C(O)=O

Chemical Details

Formal Charge0
Atom Count50
Chiral Atom Count0
Chiral Atomsn/a
Bond Count50
Aromatic Bond Count0
Leaving Atomsn/a

Drug Info: DrugBank

DrugBank IDDB00523 Different stereochemistry
  • approved
  • investigational
DescriptionAn important regulator of gene expression during growth and development, and in neoplasms. Tretinoin, also known as retinoic acid and derived from maternal vitamin A, is essential for normal growth; and embryonic development. An excess of tretinoin can be teratogenic. It is used in the treatment of psoriasis; acne vulgaris; and several other skin diseases. It has also been approved for use in promyelocytic leukemia (leukemia, promyelocytic, acute). [PubChem]
  • (2e,4e,6Z,8e)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid
  • (7e,9Z,11e,13e)-Retinoic acid
  • 9-cis-Retinoic acid
  • 9-cis-Tretinoin
  • 9(Z)-Retinoic acid
Brand Names
  • Panretin
  • Toctino
Affected OrganismHumans and other mammals
IndicationFor topical treatment of cutaneous lesions in patients with AIDS-related Kaposi's sarcoma.
PharmacologyAlitretinoin (9-<i>cis</i>-retinoic acid) is a naturally-occurring endogenous retinoid indicated for topical treatment of cutaneous lesions in patients with AIDS-related Kaposi's sarcoma. Alitretinoin inhibits the growth of Kaposi's sarcoma (KS) cells <i>in vitro</i>.
Mechanism of actionAlitretinoin binds to and activates all known intracellular retinoid receptor subtypes (RARa, RARb, RARg, RXRa, RXRb and RXRg). Once activated these receptors function as transcription factors that regulate the expression of genes that control the process of cellular differentiation and proliferation in both normal and neoplastic cells.
Route of administration
  • Cutaneous
  • Oral
  • Topical
  • Alkenes
  • Antineoplastic Agents
  • Antineoplastic and Immunomodulating Agents
  • Biological Factors
  • Carotenoids
  • D11AH04
  • L01XX22
  • 84:16.00
  • 92:00.00
CAS number5300-03-8
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682